Expression of MRP and cMOAT in Childhood Neuroblastomas and Malignant Liver Tumors and Its Relevance to Clinical Behavior

Advanced neuroblastoma and malignant liver tumor are representative childhood cancers for which combined chemotherapy including cisplatin and doxorubicin is routinely performed. The prognosis of patients with tumors which develop multiple drug resistance (MDR) is unfavorable. To elucidate the role of multidrug resistance‐associated protein (MRP) and canalicular multispecific organic anion transporter (cMOAT) in the clinical behavior of the tumors, we examined 42 neuroblastomas and 10 malignant liver tumors for the expressions of MRP and cMOAT by quantitative RNA‐polymerase chain reaction (PCR). The amplification and expression of N‐myc oncogene in the neuroblastomas were also investigated. We found a close association between MRP and N‐myc expression in each neuroblastoma sample but no significant relationship between MRP expression and the patients' outcome. The forced expression of N‐myc failed to enhance the expression of MRP in N‐myc transfected neuroblastoma cell lines. cMOAT was rarely expressed in the neuroblastomas, but was frequently expressed in the malignant liver tumors. The expression of MRP and cMOAT in the childhood liver tumors was more common and higher, especially in advanced cases with a poor outcome, than that observed in normal liver or in 9 hepatocellular carcinomas from adult patients. The enhanced expression of these genes might be characteristic of childhood malignant liver tumors and related to their clinical chemoresistance.